Nanosonics Limited

DB:OQS Stock Report

Market Cap: €605.1m

Nanosonics Valuation

Is OQS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OQS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OQS (€1.95) is trading below our estimate of fair value (€3.32)

Significantly Below Fair Value: OQS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OQS?

Key metric: As OQS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for OQS. This is calculated by dividing OQS's market cap by their current earnings.
What is OQS's PE Ratio?
PE Ratio75.3x
EarningsAU$12.97m
Market CapAU$976.84m

Price to Earnings Ratio vs Peers

How does OQS's PE Ratio compare to its peers?

The above table shows the PE ratio for OQS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average18.8x
PHH2 Paul Hartmann
12.5xn/a€742.3m
EUZ Eckert & Ziegler
24.5x5.9%€879.3m
DRW3 Drägerwerk KGaA
7.2x2.0%€798.0m
COP CompuGroup Medical SE KGaA
30.8x32.9%€775.0m
OQS Nanosonics
75.3x24.0%€976.8m

Price-To-Earnings vs Peers: OQS is expensive based on its Price-To-Earnings Ratio (75.3x) compared to the peer average (18.8x).

Price to Earnings Ratio vs Industry

How does OQS's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
OQS 75.3xIndustry Avg. 29.7xNo. of Companies8PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: OQS is expensive based on its Price-To-Earnings Ratio (75.3x) compared to the European Medical Equipment industry average (29.5x).

Price to Earnings Ratio vs Fair Ratio

What is OQS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OQS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio75.3x
Fair PE Ratio27.8x

Price-To-Earnings vs Fair Ratio: OQS is expensive based on its Price-To-Earnings Ratio (75.3x) compared to the estimated Fair Price-To-Earnings Ratio (27.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OQS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.95
€2.13
+9.3%
11.2%€2.46€1.69n/a10
Nov ’25€1.87
€2.19
+17.2%
12.1%€2.61€1.71n/a11
Oct ’25€2.24
€2.19
-2.2%
12.1%€2.61€1.71n/a11
Sep ’25€1.91
€2.12
+11.2%
12.5%€2.56€1.68n/a12
Aug ’25€1.87
€2.01
+7.5%
16.8%€2.53€1.54n/a12
Jul ’25€1.71
€1.93
+13.0%
16.4%€2.53€1.54n/a12
Jun ’25€1.67
€1.93
+15.7%
16.4%€2.53€1.54n/a12
May ’25€1.74
€1.93
+11.1%
16.4%€2.53€1.54n/a12
Apr ’25€1.62
€1.93
+19.3%
16.4%€2.53€1.54n/a12
Mar ’25€1.62
€1.93
+19.3%
16.4%€2.53€1.54n/a12
Feb ’25€1.71
€2.28
+33.6%
15.6%€3.04€1.72n/a11
Jan ’25€2.64
€2.79
+5.7%
14.7%€3.34€2.23n/a12
Dec ’24€2.42
€2.79
+15.2%
17.9%€3.90€2.19n/a12
Nov ’24€2.26
€2.79
+23.4%
17.9%€3.90€2.19€1.8712
Oct ’24€2.50
€2.85
+14.2%
17.1%€3.95€2.28€2.2412
Sep ’24€2.42
€2.72
+12.6%
18.6%€3.86€1.98€1.9113
Aug ’24€2.84
€2.87
+1.0%
17.9%€3.91€2.01€1.8713
Jul ’24€2.82
€2.89
+2.3%
19.1%€3.97€2.04€1.7112
Jun ’24€3.08
€2.89
-6.3%
19.1%€3.97€2.04€1.6712
May ’24€3.34
€2.82
-15.7%
18.8%€3.89€2.00€1.7412
Apr ’24€3.06
€2.84
-7.2%
15.5%€3.75€2.09€1.6212
Mar ’24€2.76
€2.82
+2.2%
12.9%€3.39€2.12€1.6212
Feb ’24€3.06
€2.89
-5.4%
14.3%€3.56€2.10€1.7111
Jan ’24€2.66
€2.81
+5.6%
16.4%€3.57€2.11€2.6411
Dec ’23€3.06
€2.81
-8.2%
16.4%€3.57€2.11€2.4211
Nov ’23€2.70
€2.75
+1.9%
17.6%€3.56€2.10€2.2611

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

LNA Santé

€244.9m

Engages in the management and operation of health establishments.

2N3

€23.30

7D

-5.3%

1Y

19.1%

Shandong Weigao Group Medical Polymer

HK$19.8b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.51

7D

-10.5%

1Y

-38.6%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%